Researchers from The Scripps Research Institute (TSRI) and PATH have shed light on how the human immune system recognizes the malaria parasite. Read more...
MVI PortfolioWe strategically use our resources to support and advance a range of vaccine approaches that target both humoral and cellular immunity.
Evaluation technology projectsWe partner to develop and optimize new assays and challenge models and support reference and service laboratories.
RTS,SGhana, Kenya, and Malawi to take part in WHO malaria vaccine pilot programme
Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25
16 Nov 2017
Comparative assessment of An. gambiae and An. stephensi mosquitoes to determine transmission-reducing activity of antibodies against P. falciparum sexual stage antigens
17 Oct 2017
PATH and Walter Reed Army Institute of Research announce largest-ever controlled malaria infection study
8 Sep 2017
Optimizing Direct Membrane and Direct Skin Feeding Assays for Plasmodium falciparum Transmission-Blocking Vaccine Trials in Bancoumana, Mali
5 Sep 2017
RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial
23 Aug 2017